Maria Cinta Cid, ACR 2020 – Mavrilimumab in Patients with Giant Cell Arteritis (Part 1)
We had the pleasure to talk to Maria Cinta Cid (Hospital Clinic Barcelona, Barcelona, Spain) about the use of mavrilimumab in patients with giant cell arteritis (Clinical Trial Identifier: NCT03827018). The abstract ‘Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis’ (ABSTRACT NUMBER: L06) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- Could you tell us a little about giant cell arteritis, its prognosis and incidence? (0:05)
- What is the current standard of care for giant cell arteritis, and what are the limitations of this treatment? (1:52)
- What is the mechanism of action of mavrilimumab? (6:07)
Disclosure: Maria Cinta Cid discloses receiving consulting/advisory board fees from GSK, Abbvie and Janssen, lecturing fees from Vifor and a research grant from Kiniksa. Maria Cinta Cid was regional lead for the GiACTA trial (Riche) and co-PI for the KPL-301-C001 trial with mavrilimumab.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Vasculitis
Naomi J Patel, ACR 2022: Impact of tocilizumab on HbA1C during giant cell arteritis treatment
GiACTA was a randomized, double-blind, placebo-controlled study that investigated the safety and efficacy of tocilizumab, an IL-6 receptor antagonist, in patients with giant cell arteritis. touchIMMUNOLOGY were delighted to speak with Dr. Naomi J Patel (Massachusetts General Hospital, Boston, MA, USA) to discuss the aims, design and findings from her post-hoc analysis of the GiACTA […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Lisa Christ, ACR 2022: Tocilizumab and ultra-short glucocorticoids in giant cell arteritis – one year follow-up of GUSTO
The GUSTO trial (NCT03745586) investigated the efficacy and safety of tocilizumab (TCZ )-monotherapy after ultra-short glucocorticoid treatment in new-onset giant cell arteritis (GCA). touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss this analysis of GUSTO exploring the maintenance of remission 1 year after discontinuation of TCZ treatment. This […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!